Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

Research Grant to Fund Development of Novel Tumor-Imaging Nanoprobes

By BiotechDaily International staff writers
Posted on 04 Nov 2013
Research funds have been awarded that will support a collaborative effort to develop novel nanoprobes to be used for in vivo tumor imaging.

Rockland Immunochemicals Inc. (Gilbertsville, PA, USA) and Abzyme Therapeutics (Malvern, PA, USA) have received a Phase I Small Business Innovation Research (SBIR) grant from the [US] National Cancer Institute (Bethesda, MD, USA) to develop nanoprobes for in vivo imaging of tumors that express the important cancer therapeutic targets: EGFR (epidermal growth factor receptor), Her2 (human epidermal growth factor receptor 2), or mesothelin.

According to the terms of the grant, during the first phase the partners will develop, label, and characterize high-affinity single domain antibodies against the three tumor antigens. Abzyme Therapeutics will develop the single domain antibodies, and Rockland will be responsible for bioconjugation and in vivo characterization.

In the planned second phase of the project, the key antibodies will be labeled with a radioactive isotope and characterized using PET scanners in collaboration with Yale University (New Haven, CT, USA) and the University of Pittsburg (PA, USA). Suitable radioactively labeled antibodies will be used as in vivo imaging agents, and their potential use in targeted cancer therapy will be considered.

“In these times of shrinking government investment in research, this SBIR grant validates Rockland’s business model of collaboration with leading academic institutions to aggregate, develop, and commercialize technologies that will ultimately benefit humanity,” said Jim Fendrick, president and CEO of Rockland Immunochemicals. “This research is in line with the company’s expertise in antibodies and antibody based tools. We are confident that this collaboration will generate significant innovation and that the results will have great scientific and commercial applications.”

According to the market research firm Markets and Markets (Pune, India), the global diagnostic imaging market, which stood at USD 20.7 billion in 2010, is expected to expand to USD 26.6 billion by 2016. This expected rise is attributed to an aging population, increasing awareness about preventive care, and advancements in the field.

Related Links:
Rockland Immunochemicals Inc.
Abzyme Therapeutics
[US] National Cancer Institute




comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Alternative splicing produces two protein isoforms (Photo courtesy of Wikimedia Commons).

Key Regulator of Cancer-Inducing Alternative Splicing Identified

Cancer researchers have identified the splicing factor RBM4 (RNA-binding protein 4) as a key determinant in processes that prevent tumor development and spread. RBM4 is known to be crucial to gene splicing... Read more

Drug Discovery

view channel

Ibuprofen May Restore Immune Function in Older Individuals

New research suggests that macrophages from the lungs of old mice respond differently to infections than those of young mice, and ibuprofen given to the mice reversed these changes. New research using lab mice suggests that the solution to more youthful immune function might already be a common over-the-counter pain reliever.... Read more

Therapeutics

view channel
Image: Hair follicle (blue) being attacked by T cells (green) (Photo courtesy of Christiano Lab/Columbia University Medical Center).

Hair Restoration Method Clones Patients’ Cells to Grow New Hair Follicles

Researchers have developed of a new hair restoration approach that uses a patient’s cells to grow new hair follicles. In addition, the [US] Food and Drugs Administration (FDA) recently approved a new drug... Read more

Lab Technologies

view channel
Image: Leica Microsystems launches the inverted research microscope platform Leica DMi8 (Photo courtesy of Leica Microsystems).

New Inverted Microscope Designed to Readily Adapt to Changing Research Demands

A new inverted microscope for biotech and other life science laboratories was designed to readily accommodate modifications and upgrades to allow it to keep current with changing research demands and interests.... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.